Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Hepatocyte Growth Factor (HGF) Inhibits Collagen I and IV Synthesis in Hepatic Stellate Cells by miRNA-29 Induction

  • Monika Kwiecinski ,

    Contributed equally to this work with: Monika Kwiecinski, Andrea Noetel, Natalia Elfimova

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Andrea Noetel ,

    Contributed equally to this work with: Monika Kwiecinski, Andrea Noetel, Natalia Elfimova

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Natalia Elfimova ,

    Contributed equally to this work with: Monika Kwiecinski, Andrea Noetel, Natalia Elfimova

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Jonel Trebicka,

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

  • Stephanie Schievenbusch,

    Affiliations Institute for Pathology, University Hospital Cologne, Cologne, Germany, Department of Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany

  • Ingo Strack,

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Levente Molnar,

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Melanie von Brandenstein,

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Ulrich Töx,

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany

  • Roswitha Nischt,

    Affiliation Department of Dermatology, University Hospital of Cologne, Cologne, Germany

  • Oliver Coutelle,

    Affiliation Department of Internal Medicine, University Hospital Cologne, Cologne, Germany

  • Hans Peter Dienes,

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

  • Margarete Odenthal

    Affiliation Institute for Pathology, University Hospital Cologne, Cologne, Germany

Hepatocyte Growth Factor (HGF) Inhibits Collagen I and IV Synthesis in Hepatic Stellate Cells by miRNA-29 Induction

  • Monika Kwiecinski, 
  • Andrea Noetel, 
  • Natalia Elfimova, 
  • Jonel Trebicka, 
  • Stephanie Schievenbusch, 
  • Ingo Strack, 
  • Levente Molnar, 
  • Melanie von Brandenstein, 
  • Ulrich Töx, 
  • Roswitha Nischt



In chronic liver disease, hepatic stellate cells (HSC) transdifferentiate into myofibroblasts, promoting extracellular matrix (ECM) synthesis and deposition. Stimulation of HSC by transforming growth factor-β (TGF-β) is a crucial event in liver fibrogenesis due to its impact on myofibroblastic transition and ECM induction. In contrast, hepatocyte growth factor (HGF), exerts antifibrotic activities. Recently, miR-29 has been reported to be involved in ECM synthesis. We therefore studied the influence of HGF and TGF-β on the miR-29 collagen axis in HSC.


HSC, isolated from rats, were characterized for HGF and Met receptor expression by Real-Time PCR and Western blotting during culture induced myofibroblastic transition. Then, the levels of TGF-β, HGF, collagen-I and -IV mRNA, in addition to miR-29a and miR-29b were determined after HGF and TGF-β stimulation of HSC or after experimental fibrosis induced by bile-duct obstruction in rats. The interaction of miR-29 with 3′-untranslated mRNA regions (UTR) was analyzed by reporter assays. The repressive effect of miR-29 on collagen synthesis was studied in HSC treated with miR-29-mimicks by Real-Time PCR and immunoblotting.

Principal Findings

The 3′-UTR of the collagen-1 and −4 subtypes were identified to bind miR-29. Hence, miR-29a/b overexpression in HSC resulted in a marked reduction of collagen-I and -IV synthesis. Conversely, a decrease in miR-29 levels is observed during collagen accumulation upon experimental fibrosis, in vivo, and after TGF-β stimulation of HSC, in vitro. Finally, we show that during myofibroblastic transition and TGF-β exposure the HGF-receptor, Met, is upregulated in HSC. Thus, whereas TGF-β stimulation leads to a reduction in miR-29 expression and de-repression of collagen synthesis, stimulation with HGF was definitely associated with highly elevated miR-29 levels and markedly repressed collagen-I and -IV synthesis.


Upregulation of miRNA-29 by HGF and downregulation by TGF-β take part in the anti- or profibrogenic response of HSC, respectively.


Progressive liver fibrosis due to chronic viral hepatitis, autoimmune, metabolic or hereditary disorders is a leading cause of morbidity and mortality in the Western world (reviewed in [1], [2], [3]). Regardless of the underlying etiology, liver fibrosis is characterized by an excessive deposition and reorganization of extracellular matrix (ECM) with a dramatic increase in non-collagenous and collagenous ECM proteins. The fibrillar collagen type I, is encoded by two different genes, col1A1 and col1A2, and accounts for 36% of the total collagens in ECM of healthy liver. During liver fibrogenesis, collagen type I is the predominant isoform deposited into the perisinusoidal space. However, collagen type IV, that constitutes less than 10% of total collagen in the normal liver, is most dramatically upregulated in fibrosis [4], [5], [6].

In the fibrotic liver, hepatic stellate cells (HSC) undergo myofibroblastic transdifferentiation. These myofibroblastic HSC are regarded as the main source of ECM production [1], [3], [7], [8] although portal myofibroblasts, infiltrating fibroblasts and fibrocytes may also participate in the synthesis and restructuring of the connective tissue [9], [10]. HSC get activated in response to chronic liver injury by proinflammatory and profibrogenic mediators such as transforming growth factor-β (TGF-β) [11], [12] and platelet-derived growth factor β [13], [14]. TGF-β is recognized as the main profibrogenic mediator, triggering the myofibroblastic transition of HSC. Furthermore, it promotes the synthesis of ECM proteins, and inhibits expression and activity of matrix degrading enzymes in HSC [15].

TGF-β stimulated matrix production and deposition has been shown in a wide range of models of experimental fibrosis [16], [17] and in patients with chronic hepatitis and cirrhosis [18], [19], [20]. Interestingly, there is good evidence for hepatic growth factor (HGF) opposing TGF-β signalling by reducing TGF-β mRNA levels [21]. HGF is a multifunctional cytokine that elicits mitogenic, motogenic, and morphogenic properties [22], [23] by activation of the tyrosine kinase receptor Met, a product of the proto-oncogene c-met [24], [25]. In addition, HGF is known to inhibit accumulation of extracellular matrix and development of hepatic fibrosis in vivo [26], [27], [28]. TGF-β can in turn dramatically suppress HGF mRNA expression in HSC, demonstrating the reciprocal effects of these cytokines on ECM accumulation [29].

The synthesis of extracellular matrix proteins is modulated by microRNA-29 (miR-29) in extrahepatic tissue [30], [31], [32], [33]. Recent reports suggest that miR-29 is also involved in the synthesis of collagen type I in liver fibrosis [34], [35]. The miR-29 family consists of miR-29a, miR-29b (b1, b2), and miR-29c, which differ in only two or three nucleotides, respectively. The genes for miR-29a and miR-29b1 are both located on chromosome 7, whereas the genes for miR-29c and miR-29b2 are located on chromosome 1. Each gene pair is transcribed in tandem resulting in a common pri-miRNA from which the mature miR-29 members are released after further processing [36], [37].

In the present study, we investigate the role of the members of the miR-29 family in HGF mediated repression of collagen synthesis. We demonstrate that miR-29 is not only involved in collagen type I but also in type IV synthesis of myofibroblastic HSC. The importance of miR-29 in hepatic collagen homeostasis is underlined by our in vivo data that shows the lack of miR-29 in severe experimental fibrosis after bile duct obstruction. This loss of miR-29 is suggested to be due to the response of HSC to exposure to profibrogenic mediators as shown by our in vitro findings on TGF-β stimulated HSC. Whereas TGF-β stimulation leads to decreased miR-29 levels, but to pronounced upregulation of collagen synthesis, HGF stimulation leads to elevated miR-29 expression, but to repression of collagen synthesis. Thus, our data provide detailed evidence for the antifibrotic action of miR-29 in response to HGF signalling that is counteracted by the profibrotic growth factor TGF-β.

Materials and Methods

Isolation of primary HSC from rat, cell culture and stimulation of HSC

Isolation and plastic-induced myofibroblastic in vitro activation of primary HSC was performed as previously described [38], [39]. Cells were maintained in Dulbecco's modified Eagles medium (DMEM) with 10% fetal calf serum (FCS) at 37°C and 5% CO2 in a humidified atmosphere. HSC at day 3 are considered as quiescent relative to day 7 of HSC culture, when they express all features of myofibroblasts and considered as myofibroblastic cells. For miR-29 transfection assays, HSC-T6 cells (kindly provided by SL Friedman) were cultured in agreement to the previous description [40], [41]. In order to stimulate HSC with TGF-β cells were cultured to 90% confluency in DMEM containing 10% FCS and starved out for 24 h in DMEM containing 0.5% FCS. For HGF stimulation HSC-T6 cells were cultured to a confluency of 70% in DMEM containing 10% FCS. After 24 h 10 ng/ml TGF- β1 (R&D Systems, Wiesbaden-Nordenstadt, Germany), or 40 ng/ml recombinant hHGF (Dianova, Hamburg, Germany) was added and cells were cultured for a further 24 h.


In order to search miRNA targets, the databases miRanda ( [42], [43], Targetscan ( [44], and Pictar ( [45] were queried.

Plasmid constructs

The 3′-UTR of collagen 4A1 (col4A1) and collagen 4A5 (col4A5) transcripts bearing putative miRNA-binding sites for miR-29 were amplified from genomic rat DNA using the primer shown in the Table S1. Furthermore, the putative binding sites of collagen 1A1 (col1A1), collagen 1A2 (col1A2), collagen 4A1(col4A1), and collagen 4A5 (col4A5) as well as the corresponding mutants containing two point mutations were cloned by insertion of the dimerized oligonucleotides shown in the Table S2. Amplicons and oligonucleotide dimers were cloned downstream of the renilla luciferase reporter of the psiCHECKTM-2 vector (Ambion, Austin, USA) (Figure 1 A).

Figure 1. Met and HGF expression in primary and immortalized HSC.

Total RNA was extracted from primary rat HSC after the third, fifth and seventh day of cell culture (3d, 5d, 7d) and from myofibroblastic HSC-T6 cells. Subsequently, c-met and HGF expression was determined (A–C). The c-met and HGF transcript levels were quantified by Real-Time PCR and normalized using HPRT as house-keeping gene (A–C). The expression of c-met increased during the differentiation process of primary HSC and achieved the highest level in the immortalized cell line HSC-T6 representing a myofibroblastic phenotype [41], whereas HGF levels were shown to be opposite (A, B). Primary HSC at the 3rd culture day (prim. HSC) and immortalized HSC (HSC-T6) were either untreated (−) or stimulated with TGF-β (+) and RNA levels of c-met and HGF were analyzed by Real-Time PCR (C). The Met protein expression in HGF and TGF-β stimulated HSC-T6 (+HGF, +TGF-β) in comparison to untreated HSC-T6 cells (control) was shown by Western blot analysis (D).

miRNA transfection and reporter assays

miRNA mimicking miR-29a, miR-29b and a scrambled miRNA control were obtained from Dharmacon (Lafayette, USA). HSC were seeded in 6-well plates, incubated overnight to a density of 90% and transfected using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) as instructed. Afterwards, the cells were lysed either in SDS-lysis buffer (15 mM Tris-HCL pH 6.8, 0.5% SDS, 2.5% glycerol) containing protease inhibitors (Roche Applied Science, Mannheim, Germany) or in Qiazol (Qiagen, Hilden, Germany) and stored for subsequent protein or RNA analyses, respectively.

For reporter assays, cells were seeded in 24-well plates to reach 90% confluency overnight. 50 nM miRNA and 2 µg/ml psiCHECKTM-2 reporter was used for transfection using Lipofectamine 2000. The level of miR-29 transfected into HSC-T6 cells was analyzed by Real-Time PCR, demonstrating stable levels between 8 h and 48 h post-transfection. Cells were therefore harvested 24 hours after transfection and luciferase activity in the samples was determined using the Dual Luciferase Reporter Assay System (Promega, Mannheim, Germany) according to the manufacturer's recommendations. All samples were measured in triplicate and experiments were each performed three times.

Total RNA extraction

Total RNA from snap-frozen cell culture and tissue samples was isolated using the Qiazol reagent as instructed (Qiagen, Hilden, Germany). Rat liver tissues were homogenized using the Precellys 24 tissue homogenizer (Peqlab Biotechnologie, Erlangen, Germany) prior to extraction. Total RNA yields were determined by A260 measurement using the ND-1000 NanoDrop spectrophotometer (NanoDrop, Wilmington, USA) and RNA integrity was assessed by microcapillary electrophoresis (2100 BioAnalyser, Agilent Technolologies, Waldbronn, Germany).

Quantifying microRNA by Real-Time PCR

microRNA was quantified by a two-step Real-Time PCR using the miScript-Reverse Transcription Kit and the miRNA-SYBR Green PCR Kit (Qiagen, Hilden, Germany). The first step includes total RNA polyadenylation and reverse transcription, followed by Real-Time PCR. Primers used for cDNA synthesis and Real-Time PCR were selected and purchased from the GeneGlobe Search Center (Qiagen). 2 ng of all samples were used and processed in triplicate in agreement with the supplier's guidelines. Cellular miRNA levels were normalized using RNU6 as reference RNA.

Transcript quantification by Real-Time PCR

Total RNA concentrations were estimated by A260 measurement. 1 µg of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Applera, Darmstadt, Germany) as instructed. 10 ng of cDNA were used for Real-Time PCR using specific primers listed in Table S1 B and Power SYBR Green PCR Mastermix (Applied Biosystems Applera). All reactions were performed in triplicate. Transcript levels were evaluated by absolute quantification using an on-line standard curve and corrected by normalization to the house-keeping gene, hypoxanthine phosphoribosyltransferase (HPRT).


Total protein concentrations were determined using the BCA protein assay (Thermo Scientific, Bonn, Germany). Equal amounts of protein (10 µg) were resolved on 4–12% SDS-polyacrylamid gels (Biorad, München, Germany), electrotransferred to Hybond ECL nitrocellulose membranes (Amersham Biosciences, München, Germany) and immunostained with the anti-collagen I (1∶1000), anti-collagen IV (1∶5000) antibodies, both from Abcam (Cambridge, UK), or with anti-Met antibodies (1∶500) from Santa Cruz (Heidelberg, Germany), or anti-actin antibodies (1∶5000) from Sigma-Aldrich (Hamburg, Germany). Signals were visualized and quantified using enhanced chemiluminescence (ECL) substrate and a FLUORCHEM®FC2 Alpha Ease scanner (Biozym, Hess. Oldendorf, Germany).

Induction of biliary fibrosis by bile duct occlusion in rats

10 male Wistar rats (250–300 g) were housed in individual cages with free access to regular chow and water. All experiments were conducted in accordance with National Health and Medical Research Committee Guidelines for Animal Experimentation and approved by the local veterinary authority of North Rhine Westphalia (reference number: K07,04/03). 5 animals were sham operated and 5 animals were subjected to bile duct occlusion (BDO) as described previously [46], [47]. Livers were snap frozen in liquid nitrogen and stored at minus 80°C for analysis of mRNA, protein expression, and hydroxyproline content as described before [47]. Liver tissue from liver segment IV was fixed in 4% buffered formaldehyde solution and embedded in paraffin for histopathological evaluation after Gomori, HE and Elastica van Gieson staining.

Statistical analysis

Statistical analyses were performed using SPSS software 17 (Chicago, IL, USA). Data obtained from rat tissues was shown as boxplots and subjected to analyses of variance (ANOVA) using Dunnetts post-hoc comparison. Bar graphs show means ± SEM and values of p < 0.05 were considered statistically significant.


HGF is known to suppress fibrosis [26], [27], [28] and its antagonistic interaction with the TGF-β pathway leading to collagen suppression has recently been shown in renal fibroblasts [48], [49]. Here, we studied the function of HGF in collagen synthesis of primary HSC undergoing myofibroblastic activation after primary culture for up to 7 days. Myofibroblastic transition of primary HSC in culture resembles the process in vivo and is characterized by the loss of vitamine A, increased proliferation, and elevated expression of profibrogenic mediators and various connective tissue proteins [5], [11], [29], [39]. The most prominent feature of the myofibroblastic transdifferentiation process, in vitro and in vivo, is the enhanced expression of α-smooth muscle actin (SMA). Therefore, we first demonstrated the process of myofibroblastic transdifferentiation by analysis of the induced SMA expression of isolated rat HSC in culture (Figure S1).

The myofibroblastic transition of primary HSC was accompanied by a reduction in HGF transcripts and a simultaneous increase in the HGF receptor, c-met (Figure 1 A, B). The opposite effects in HGF and c-met expression were most pronounced in HSC of the HSC-T6 cell line, representing fully transdifferentiated myofibroblastic HSC [41]. In HSC-T6 HGF transcripts were lost while the c-met levels were high (Figure 1 A). Interestingly, TGF-β stimulation of both, HSC at day 3 of primary culture and of myofibroblastic HSC-T6 cells was capable of downregulating HGF and further upregulating c-met (Figure 1 C). In line with the transcriptional response, Met protein synthesis increased after TGF-β exposure in HSC, but decreased after stimulation with HGF (Figure 1 D).

HGF generates antifibrotic effects in HSC by repression of the collagen I and collagen IV synthesis and attenuating the TGF-β expression

TGF-β is a highly potent profibrogenic growth factor that activates and promotes collagen synthesis in HSC [4], [12]. Whereas stimulation of HSC with TGF-β induced the expression of various collagen subunits such as col1A1, col1A2, col4A1, col4A5 in addition to TGF-β, itself, the HGF transcript levels were markedly repressed (Figure 2 A).

Figure 2. Contrary influence of TGF-β and HGF stimulation on collagen, but also on TGF-β and HGF expression, itself.

Collagen 1A1 (col1A1), collagen 1A2 (col1A2), collagen 4A1 (col4A1), and collagen 4A5 (col4A5), HGF and TGF-β mRNA levels were compared by Real-Time PCR in untreated (−) and in HSC-T6 cells stimulated either with TGF- β (+TGF- β) (A) or with HGF (+HGF) (B).

In contrast to TGF-β treatment, the stimulation of HSC with HGF lead to reduced expression of col1A1, col1A2, col4A1, and col4A5, as well as TGF-β expression. However, there was no remarkable change of HGF expression (Figure 2 B).

miR-29a and miR-29b regulate collagen I and IV synthesis in activated HSC

Since miRNA has been shown to profoundly affect gene regulation, we screened different databases, in order to detect miRNA candidates that inhibit collagen I and IV synthesis in HSC upon HGF stimulation. In the 3′UTR sequences of the collagen-1 and collagen-4 mRNA, potential binding sites for the members of the let-7 family were detected. A number of other miRNA species that might affect collagen type-I and -IV synthesis, such as miR-106a/b, miR-20a/b, miR-26a/b, miR-374a/b, miR-186 were also identified by in silico analyses (summarized in Table 1). Strikingly, all of the collagen-1 and -4 transcripts contained binding sites for members of the miRNA-29 family in their 3′UTR (Table 1). Since miR-29 is thought to be involved in modulating expression of extracellular matrix components (Table S3) [30], [31], [32], [34], this makes them promising candidates for collagen I and IV repression after HGF stimulation of HSC.

Table 1. miRNAs with putative binding sites in transcripts of collagen 1 and 4.

First, we analyzed the synthesis of miR-29 in quiescent and myofibroblastic HSC. Interestingly, the expression of mature miR-29a, but not of miR-29b, was contrary to the collagen expression during myofibroblastic transition. Thus, whereas col1A2 and col4A1 collagen expression was highly increased in myofibroblastic HSC, the levels of miR-29a were suppressed (Figure 3 A, B). Analysis of the transcriptional levels of the primary precursor miRNA (pri-miRNA) revealed that pri-miR-29b/c transcript levels are only moderately suppressed, but that the miR-29a/b gene of chromosome 7 undergoes predominant transcriptional repression upon myofibroblastic transition of HSC.

Figure 3. Reciprocal expression of the collagen subunits, col1A1 and col4A2, and primary and mature miR-29.

RNA of primary HSC in the quiescent stage (day 3 of primary culture) and after myofibroblastic activation (day 7 of primary culture) was analyzed for mRNA col1A2 and col4A1 levels (A), as wells as for the levels of mature miR-29a and miR-29b (B), and the primary transcripts of the miR-29a/b and miR-29b/c gene (C).

In order to study miR-29 function in collagen synthesis, we inserted the 3′-UTR sequences downstream of a luciferase reporter (Figure 4 A). During progression of liver fibrosis, collagen IV is most prominently upregulated among ECM components [6]. Therefore, in addition to collagen-1, the collagen-4 mRNA could be an important target of miR-29 in HSC after HGF stimulation. Indeed, insertion of the 3′-UTR of col4A1 and col4A5 downstream of the luciferase reporter gene lead to a reduction in luciferase expression after treatment of HSC with ago-miR-29a, mimicking miR-29a (Figure 4).

Figure 4. miR-29 interaction with the 3′-UTR of col4A1 and col4A5 transcripts.

The 3′-UTR of col4A1 (1382 bp) or col4A5 (786 bp) mRNA was subcloned downstream of the Renilla luciferase reporter (hRluc) of the psiCHECKTM-2 vector (A). Reporter plasmids were cotransfected into HSC-T6 in combination with scrambled miRNA or miR-29a mimic (ago-miR-29a), respectively, and luciferase reporter expression was determined by the hRluc luminescence measurement normalized to firefly luminescence (hluc+) (B–C).

Among the putative miR-29 binding sites of the collagen mRNA (shown in the Table S4), the following sites were chosen for our further analyses, due to the suggestions of Bartel et al. [50] to function most likely as an inhibitory miR-29 interaction sequence: the region of positon 29–35 in the col4A1 3′-UTR, of postion 404–410 in the col4A5, positon 903–909 in the col1A1, and of position 506–512 in the col1A2 3′-UTR (Table S4). To demonstrate the specificity of miR-29 for the binding sites, in the 3′-UTRs two point mutations were incorporated to abolish the putative miR-29 recognition sequences of the collagen-4 mRNA (col4A1, col4A5) and collagen-1 transcripts (col1A1 and col1A2). Co-transfection of HSC-T6 with the reporter plasmids and ago-miR-29a reduced reporter activity of the wild type controls, but not of the mutated collagen type I and IV constructs (Figure 5 A–D).

Figure 5. Interaction of miR-29a with the binding regions of col1A1, col1A2, col4A1 and col4A5 3′-UTR transcripts.

Putative miR-29 binding sites in the collagen col1A1 (A), col1A2 (B), col4A1 (C) and col4A5 (D) 3′-UTR (wt) and the corresponding mutated sequences (mu) carrying two point mutations (bold and underlined) were cloned into psiCHECKTM-2 vector. The reporter plasmids were co-transfected into HSC-T6 cells with either scrambled miRNA or miR-29a mimic (ago-miR-29a), respectively. Insertion of the miR-29 binding sites (wt), but not with mutated binding site (mu), resulted in reduced reporter gene expression by miR-29a treated HSC (A–D).

Furthermore, transfection of ago-miR-29a and ago-miR-29b into HSC suppressed transcription and protein synthesis of collagen type I and IV ((Figure 6A, B). Together, these data demonstrated that miR-29 specifically inhibits transcription and protein expression of collagen I and IV. In order to analyze if other features of myofibroblastic transition were affected by miR-29, we determined SMA expression in miR-29 treated HSC, because increased SMA assembly is one of the most important features of myofibroblastic transition (Figure S1 A). However, overexpression of miR-29 in myofibroblastic HSC did not affect the expression of SMA (Figure S1 D).

Figure 6. Repression of collagen synthesis by miR-29a and miR-29b.

mRNA quantification of collagen subunits in HSC treated either with miR-29a, miR-29b (ago-miR-29a, ago-miR-29b), or scrambled miRNA by Real-Time PCR (A). The col1A1, col1A2, col4A1, and col4A5 mRNA levels were normalized to HPRT expression. Furthermore, collagen I and IV protein levels (col I, col IV) were determined by immunoblotting and subsequent densitometric quantification (B).

miR-29a and miR-29b are downregulated during experimental liver fibrosis in rat

Next, we induced experimental fibrosis by bile duct occlusion (BDO) in rats and studied the miRNA-29 expression during liver fibrogenesis. After four weeks of BDO both hepatic inflammation and collagen accumulation was evident in histological sections (Figure 7 A). Hydroxyproline determination indicates significant enhancement of matrix deposition in BDO treated livers (Figure 7 B). Thus, BDO induced severe liver fibrosis, when compared to livers of sham-operated animals. Consistent with the antifibrogenic and inhibitory function of miR-29 in collagen I and IV synthesis and the increase of col1A2 and col4A2 (Figure 7 B), we observed a significant reduction in hepatic miR-29a and miR-29b levels in this experimental BDO model (Figure 7 C). This loss of the miR-29a and miR-29b in fibrotic BDO treated livers is attended by reduced levels of HGF upon fibrosis (Figure 7 D).

Figure 7. Reduced miR-29a and miR-29b expression in livers after BDO.

Liver tissues from bile duct obstructed (BDO) rats showed hepatic inflammation and fibrosis shown by haematoxylin-eosin (HE), van Gieson, and Gomori staining (A). HE histology clearly shows the loss of liver architecture and inflammation after BDO. van Gieson and Gomori stainings revealed the enhancement of connective tissue and the formation of septa (arrows indicate matrix deposition stained in red by van Gieson or in dark brown by Gomori, respectively). Hydroxyproline levels in livers of sham operated (N = 5) and of BDO rats (N = 5) were determined and col1A2 and col4A2 mRNA levels were quantified by Real Time PCR (B). Additionally, miR-29a and miR-29b levels (C) and HGF and c-met transcripts (D) were quantified by Real-Time PCR. While miR-29 and HGF expression was significantly reduced (C,D), hydroxyproline and collagen mRNA were signifcantly increased in BDO livers (B) (*: p<0.05 **:p<0.01; ***: p<0.001).

miR-29 synthesis in HSC is suppressed by TGF-β, but promoted by HGF

Stimulation of primary HSC and myofibroblastic HSC-T6 cells with TGF-β decreased significantly the expression of miR-29a and miR-29b in vitro (Figure 8). In contrast, the incubation of primary and transdifferentiated HSC with the recombinant hHGF elicited a marked upregulation of the miR-29a/b levels (Figure 8). To address the question if the antagonistic influence of TGF-β and HGF can be also observed in other species or fibroblastic cells of other organs, we stimulated primary skin fibroblasts with both TGF-β and HGF. In agreement with the data on rat HSC, miR-29 is repressed by TGF-β, but upregulated by HGF (Figure S2).

Figure 8. Contrary effects of HGF and TGF-β on miR-29 expression in HSC.

miR-29a expression in HSC after 3 days (3d) of primary culture (A) and miR-29a and miR-29b expression in myofibroblastic HSC-T6 (B). HSC were not stimulated (−) or treated (+) with either TGF-β or hHGF and miR-29a/b levels were determined by Real Time-PCR analysis.

Therefore, miR-29 expression appears to be reciprocally regulated by profibrogenic (TGF-β) and antifibrogenic growth factors (HGF) in HSC, suggesting that miR-29 occupies a central role in responding to the antagonistic actions of HGF and TGF-β in regulating collagen synthesis in activated and transdifferentiated HSC.

Overexpression of miR-29 can overcome TGF-β mediated induction of col1A1

After demonstrating that repression of the collagen-inhibiting miR-29 is an important downstream TGF–β effect, we studied if miR-29 overexpression can overcome the profibrogenic features mediated by TGF-β such as col1A1 induction. For this purpose, HSC-T6 cells were transfected with miR-29a mimics (ago-miR29a) in comparison to scrambled or miR-29-silencing miRNA (antago-miR-29). Transfection of HSC with miR-29a mimics lead to a 10-fold overexpression of miR-29a. In HSC that express low levels of miR-29a due to transfection with scrambled miRNA or with a miR-29a silencer, TGF-β treatment highly induced col1A1 synthesis. However, col1A1 induction by TGF-β was only marginal in HSC, that highly overexpress miR-29a after transfection with miR-29a mimics (Figure 9). Thus, miR-29a is able to lower significantly the profibrogenic features of TGF-β in collagen induction.

Figure 9. Diminished effect of TGF-β on col1A1 expression in miR-29 treated HSC.

The myofibroblastic HSC-T6 cells were transfected with scrambled miRNA, miR-29 mimic (ago-miR-29), or with a miR-29 silencer (antago-miR-29). TGF-β treatment resulted in highly increased col1A1 expression in HSC cells treated with scrambled miRNA or with antago-miR-29, but only a moderate col1A1 induction in miR-29 overexpressing HSC after transfection with ago-miR-29.


In the present study we investigated the effects of the opposing action of TGF-β and HGF on miR-29 regulated collagen synthesis by HSC during liver fibrosis. After transdifferentiation into myofibroblasts, HSC constitute the main matrix producing cell type of the fibrotic liver [1], [4]. Our findings demonstrate that myofibroblastic transdifferentiation is accompanied by the loss of HGF synthesis on the one hand, and a tremendous increase of Met receptor expression on the other hand (Figure 1). Previous data have shown that the transition of HSC into myofibroblasts is triggered by paracrine but also by autocrine TGF-β stimulation [12], [51]. Accordingly, TGF-β treatment of HSC leads to decreased HGF expression [29], but enhanced Met receptor synthesis (Figure 1). Although Ikeda et al have suggested that Met receptor expression only occurs in myofibroblastic HSC, its upregulation in response to TGF-β and its association with the pro-fibrotic effects of TGF-β has not been previously shown. TGF-β is the main fibrotic mediator that I) induces the synthesis of ECM components such as collagen type-I and -IV and other collagens [19] II) influences the balance of matrix metalloproteinase (MMP) secretion and their inhibitors [52], and III) affects a wide range of growth factor expression profiles in HSC [1], [4]. The opposed effect of TGF-β on HGF expression and its receptor Met demonstrates that the changing role of HSC in the paracrine HGF stimulation - from a HGF-releasing cell type to a HGF-influenced cell type - is embedded in the regenerative and fibrotic alterations upon chronic liver disease.

Thus, HSC take center stage during fibrosis in responding to the opposing effects of TGF-β and HGF on collagen synthesis. In renal fibroblasts, Yang et al. showed that converse signaling of HGF and TGF-β is due to competition for ERK1/2 mediated inhibition of smad2/3 phoshorylation [48]. Upon TGF-β stimulation of HSC smad2/3 act as the main signal transducers initiating ECM synthesis and myofibroblastic α-smooth-muscle actin expression [12], [51], whereas HGF attenuates TGF-β induced Smad-2/3 nuclear translocation and accumulation [48]. However, blocking of the smad pathway by RNA interference displays that not only the Erk1/2 inhibitory effect on the smad2/3 pathway, but also the HGF mediated activation of Akt pathway is involved in repressing the profibrogenic signalling TGF- β by HGF [49].

In the present study, we now collect evidence that in response to the counteracting HGF / TGF-β signals the miR-29 levels in HSC are contrarily regulated. Recent reports have shown that altered miRNA levels are associated with the phenotypical changes of HSC during the myofibroblastic transition process including the induction of ECM proteins [53], [54]. Our in silico target analyses identified various miRNA species putatively suppressing collagen synthesis. In this respect, the members of the miR-29 family are the most promising candidates because they are repressed during myofibroblastic transition and they hold highly conserved binding sites in the 3′-UTR of the various subunits of collagen 1 and 4 (Table 1). Indeed, our in vitro data reveal a definite inhibition of collagen type IV, that is the most upregulated collagen form in the fibrotic liver [6], by miR-29. These findings are in agreement with the data of Du et al. [33] and recent reports showing the miR-29 regulation of elastin, fibullin and collagen I synthesis [30], [31], [32], [34], [35].

Keeping with the antifibrotic function of miR-29, miR-29 is reduced in liver biopsies after liver intoxication in mice and after chronic liver disease in humans [35]. The reduced levels of miR-29 during fibrosis are associated with an increase of extracellular miR-29 in serum depending on the fibrotic stage (manuscript in preparation). Furthermore, our in vitro and in vivo studies on HSC or on BDO-treated fibrotic livers, respectively, suggest that the loss of miR-29 in HSC after TGF-β exposure and during liver fibrogenesis leads to the abolishment of collagen type I and IV repression. Conversely, upregulation of miR-29 levels was observed after stimulation of HSC with the antifibrotic mediator HGF (Figure 8), previously shown to inhibit expression of various collagens [21], [48], [49]. Interestingly, our findings proved that upregulation of miR-29a efficiently can overcome the profibrogenic influence of TGF-β on collagen synthesis (Figure 9). Thus, our findings convincingly demonstrate that HGF mediates antifibrotic signals by influencing miR-29 expression and thereby counteracting the profibrotic activity of TGF-β.

Supporting Information

Figure S1.

α-SMA expression in HSC. During myofibroblastic transition of primary HSC in culture (A) and in the HSC-T6 cells after HGF (B) and TGF-β treatment (C). SMA expression was shown by immunochemistry using the monoclonal FITC-labeled 1A4 SMA antibody (Sigma Aldrich) (A) or by real-time PCR (B-D). Transfection of HSC-T6 with ago-miR-29a or ago-miR-29b did not result in altered SMA expression when compared to scrambled miRNA treated HSC-T6 cells.



Figure S2.

miR-29 expression in human skin fibroblasts after stimulation with HGF. Human primary skin fibroblasts, isolated and cultured according to Zhang et al. (J. Cell Sci, 119 (Pt 9): 1886–1895), were not stimulated (/) or treated for 24 h with 40 ng hHGF or 10 ng TGF-β as described in “Material and Methods” for the stimulation procedure of HSC-T6 cells. miR-29a levels were determined by Real Time-PCR analysis.



Table S1.

Oligonucleotides used for PCR assays.



Table S2.

Oligonucleotides used for dimerization and insertion into the reporter plasmid psiCHECKTM-2.



Table S3.

Ranking list of putative collagen targets from miR-29*.



Table S4.

Putative binding sites of the members of the miR-29 family to the 3′-UTR of different collagens.




We greatly appreciate the excellent technical assistance of Melanie Ruhrlaender.

Author Contributions

Conceived and designed the experiments: MO MK. Performed the experiments: MK NE AN SS IS LM UT MvB. Analyzed the data: NE AN MK OC RN JT. Contributed reagents/materials/analysis tools: HPD UT MO. Wrote the paper: OC MO. Performed the illustrations of the data: MK AN NE.


  1. 1. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655–1669.
  2. 2. Schuppan D, Krebs A, Bauer M, Hahn EG (2003) Hepatitis C and liver fibrosis. Cell Death Differ 10: Suppl 1S59–67.
  3. 3. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM (2008) Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 23: 1024–1035.
  4. 4. Gressner AM, Weiskirchen R (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10: 76–99.
  5. 5. Geerts A, Schuppan D, Lazeroms S, De Zanger R, Wisse E (1990) Collagen type I and III occur together in hybrid fibrils in the space of Disse of normal rat liver. Hepatology 12: 233–241.
  6. 6. Milani S, Herbst H, Schuppan D, Surrenti C, Riecken EO, et al. (1990) Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. Am J Pathol 137: 59–70.
  7. 7. Hautekeete ML, Geerts A (1997) The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 430: 195–207.
  8. 8. Friedman SL (1999) Stellate cell activation in alcoholic fibrosis–an overview. Alcohol Clin Exp Res 23: 904–910.
  9. 9. Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, et al. (1999) Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117: 1205–1221.
  10. 10. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, et al. (2006) Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45: 429–438.
  11. 11. De Bleser PJ, Niki T, Rogiers V, Geerts A (1997) Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 26: 886–893.
  12. 12. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, et al. (2001) Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 502: 4–10.
  13. 13. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE (1989) Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84: 1786–1793.
  14. 14. Pinzani M, Knauss TC, Pierce GF, Hsieh P, Kenney W, et al. (1991) Mitogenic signals for platelet-derived growth factor isoforms in liver fat-storing cells. Am J Physiol 260: C485–491.
  15. 15. Verrecchia F, Mauviel A (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13: 3056–3062.
  16. 16. Armendariz-Borunda J, Seyer JM, Kang AH, Raghow R (1990) Regulation of TGF beta gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J 4: 215–221.
  17. 17. Czaja MJ, Weiner FR, Flanders KC, Giambrone MA, Wind R, et al. (1989) In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 108: 2477–2482.
  18. 18. Annoni G, Weiner FR, Zern MA (1992) Increased transforming growth factor-beta 1 gene expression in human liver disease. J Hepatol 14: 259–264.
  19. 19. Castilla A, Prieto J, Fausto N (1991) Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 324: 933–940.
  20. 20. Nagy P, Schaff Z, Lapis K (1991) Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology 14: 269–273.
  21. 21. Yasuda H, Imai E, Shiota A, Fujise N, Morinaga T, et al. (1996) Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 24: 636–642.
  22. 22. Galimi F, Brizzi MF, Comoglio PM (1993) The hepatocyte growth factor and its receptor. Stem Cells 11: Suppl 222–30.
  23. 23. Michalopoulos GK (1990) Liver regeneration: molecular mechanisms of growth control. Faseb J 4: 176–187.
  24. 24. Bardelli A, Ponzetto C, Comoglio PM (1994) Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J Biotechnol 37: 109–122.
  25. 25. Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834–848.
  26. 26. Matsuda Y, Matsumoto K, Ichida T, Nakamura T (1995) Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 118: 643–649.
  27. 27. Matsuda Y, Matsumoto K, Yamada A, Ichida T, Asakura H, et al. (1997) Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 26: 81–89.
  28. 28. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, et al. (1999) Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226–230.
  29. 29. Ramadori G, Neubauer K, Odenthal M, Nakamura T, Knittel T, et al. (1992) The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is downregulated during cell growth and by transforming growth factor-beta. Biochem Biophys Res Commun 183: 739–742.
  30. 30. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, et al. (2009) Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 284: 15676–15684.
  31. 31. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027–13032.
  32. 32. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, et al. (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. pp. 1733–1743.
  33. 33. Du B, Ma LM, Huang MB, Zhou H, Huang HL, et al. (2010) High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 584: 811–816.
  34. 34. Ogawa T, Iizuka M, Sekiya Y, Yoshizato K, Ikeda K, et al. (2010) Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun 391: 316–321.
  35. 35. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, et al. (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology.
  36. 36. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, et al. (2010) Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 110: 1155–1164.
  37. 37. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, et al. (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14: 369–381.
  38. 38. Ramadori G, Veit T, Schwogler S, Dienes HP, Knittel T, et al. (1990) Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol 59: 349–357.
  39. 39. Geerts A, Vrijsen R, Rauterberg J, Burt A, Schellinck P, et al. (1989) In vitro differentiation of fat-storing cells parallels marked increase of collagen synthesis and secretion. J Hepatol 9: 59–68.
  40. 40. Sauvant P, Sapin V, Abergel A, Schmidt CK, Blanchon L, et al. (2002) PAV-1, a new rat hepatic stellate cell line converts retinol into retinoic acid, a process altered by ethanol. Int J Biochem Cell Biol 34: 1017–1029.
  41. 41. Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, et al. (2000) An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res 41: 882–893.
  42. 42. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. (2004) Human MicroRNA targets. PLoS Biol 2: e363.
  43. 43. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The resource: targets and expression. Nucleic Acids Res 36: D149–153.
  44. 44. Creighton CJ, Nagaraja AK, Hanash SM, Matzuk MM, Gunaratne PH (2008) A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 14: 2290–2296.
  45. 45. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495–500.
  46. 46. Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D (1996) Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis. J Hepatol 25: 79–84.
  47. 47. Tox U, Scheller I, Kociok N, Kern MA, Klanac D, et al. (2007) Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis. Dig Dis Sci 52: 1995–2005.
  48. 48. Yang J, Dai C, Liu Y (2003) Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 163: 621–632.
  49. 49. Schievenbusch S, Strack I, Scheffler M, Wennhold K, Maurer J, et al. (2009) Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts. Biochem Biophys Res Commun 385: 55–61.
  50. 50. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
  51. 51. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM (2000) Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 31: 1094–1106.
  52. 52. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, et al. (2003) Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124: 147–159.
  53. 53. Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, et al. (2009) Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. Febs J 276: 5163–5176.
  54. 54. Ji J, Zhang J, Huang G, Qian J, Wang X, et al. (2009) Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 583: 759–766.